Ardelyx (NASDAQ:ARDX – Get Free Report) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings and profitability.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Ardelyx and Kiora Pharmaceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ardelyx | 1 | 1 | 8 | 2 | 2.92 |
| Kiora Pharmaceuticals | 1 | 0 | 0 | 0 | 1.00 |
Ardelyx presently has a consensus price target of $13.60, suggesting a potential upside of 340.13%. Given Ardelyx’s stronger consensus rating and higher probable upside, research analysts plainly believe Ardelyx is more favorable than Kiora Pharmaceuticals.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Ardelyx | -11.85% | -35.30% | -10.23% |
| Kiora Pharmaceuticals | N/A | -82.06% | -55.72% |
Risk & Volatility
Ardelyx has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.12, meaning that its stock price is 112% less volatile than the S&P 500.
Insider and Institutional Ownership
58.9% of Ardelyx shares are held by institutional investors. Comparatively, 77.0% of Kiora Pharmaceuticals shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 0.5% of Kiora Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings and Valuation
This table compares Ardelyx and Kiora Pharmaceuticals”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ardelyx | $407.32 million | 1.91 | -$61.60 million | ($0.22) | -14.05 |
| Kiora Pharmaceuticals | $16.02 million | 0.34 | -$10.84 million | ($2.51) | -0.49 |
Kiora Pharmaceuticals has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Ardelyx beats Kiora Pharmaceuticals on 11 of the 14 factors compared between the two stocks.
About Ardelyx
Ardelyx, Inc. is a biopharmaceutical company that develops and commercializes medicines for kidney and gastrointestinal diseases. Founded in 2007, the company has focused on treatments that work in the gastrointestinal tract, including therapies based on tenapanor. Ardelyx markets IBSRELA (tenapanor) in the United States for adults with irritable bowel syndrome with constipation. It also markets XPHOZAH (tenapanor) to help control serum phosphorus in adults with chronic kidney disease who are on dialysis.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company focused on developing treatments for retinal and other eye diseases. Its research centers on therapies intended to address conditions with limited treatment options. The company’s pipeline includes KIO-301, an investigational photoswitch designed to restore light sensitivity in people with retinitis pigmentosa and other inherited retinal degenerative diseases. Kiora is also developing KIO-101, an investigational therapy for inflammatory eye diseases, including non-infectious uveitis.
Receive News & Ratings for Ardelyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx and related companies with MarketBeat.com's FREE daily email newsletter.
